20 September 2017

Glythera taps Iontas for antibodies to guide next-generation ADCs

Glythera has struck a deal to access a source of antibodies against specified targets. Iontas will use its phage display libraries and other antibody discovery capabilities to provide Glythera with a key component of its planned antibody drug conjugates (ADCs). The companies will collaboratively choose and optimize the antibodies. Beyond that, Glythera has sole responsibility for development, manufacturing and potentially commercialization of the ADCs. Source: Fierce Biotech 20/9/2017

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).